Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy

Journal of Infectious Diseases

Volumn 190, Issue 2, 2004, Pages 285-292

  Recsky, Magdalena A ^a   Brumme, Zabrina L ^a   Chan, Keith J ^a   Wynhoven, Brian ^a   Yip, Benita ^a   Dong, Winnie W Y ^a   Heath, Katherine V ^a   Montaner, Julio S G ^a,b   Levy, Adrian R ^a   Hogg, Robert S ^a,b   Harrigan, P Richard ^a,b,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC Center for Excellence in HIV/AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACCIDENT; ADULT; ARTICLE; BLOOD SAMPLING; CANADA; CONTROLLED STUDY; DEATH; DRUG EXPOSURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS LOAD;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 3242683096     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422007     Document Type: Article

References (23)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997; 349:1294.
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30.
4. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001; 285:1308-15.
5. Messeri P, Lee G, Abramson DM, Aidala A, Chiasson MA, Jessop DJ. Antiretroviral therapy and declining AIDS mortality in New York City. Med Care 2003; 41:512-21.
6. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
7. Valdez H, Chowdhry TK, Asaad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001; 32:1487-93.
8. Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36:1030-8.
9. Kuritzkes DR. Clinical significance of drug resistance in HIV-1 infection. AIDS 1996; 10(Suppl 5):S27-31.
10. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998; 177: 1521-32.
11. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-83.
12. Petrella M, Brenner B, Loemba H, Wainberg MA. HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries. Drug Resist Updat 2001; 4:339-46.
13. Pillay D, Taylor S, Richman DD. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol 2000; 10:231-53.
14. Pillay D. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population. Antivir Ther 2001; 6:15-24.
15. Harrigan PR, Côté HCF. Clinical utility of testing human immunodeficiency virus for drug resistance. Clin Infect Dis 2000; 30(Suppl 2): S117-22.
16. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
17. Wood E, Montaner JSG, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis 2003; 188:1164-70.
18. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000; 23:360-1.
19. Alexander CS, Dong W, Chan K, et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 2001; 15:601-7.
20. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2002; 10:21-25.
21. Beinker NK, Mayers DL, Lange CG, et al. Genotypic drug resistance and cause of death in HIV-infected persons who died in 1999. J Acquir Immune Defic Syndr 2001; 28:250-3.
22. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-8.
23. Richman DD, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US [abstract LB-17). In: Program and abstracts of the 41st International Conference on Antimicrobial Agents and Chemotherapy (Chicago). American Society for Microbiology: Washington, DC, 2001.